Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review

British Journal of Anaesthesia

Volumn 120, Issue 5, 2018, Pages 914-927

  Boer, C ^a   Meesters, M I ^a   Veerhoek, D ^a   Vonk, A B A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

anticoagulants; cardiopulmonary bypass; haemostasis; heparin

Indexed keywords

BLOOD CLOTTING FACTOR; HEPARIN; PROTAMINE; ANTICOAGULANT AGENT; HEPARIN ANTAGONIST;

ANAPHYLAXIS; ANTIBODY PRODUCTION; ANTICOAGULATION; BLOOD CLOT; BLOOD CLOTTING TIME; BRADYCARDIA; COMPLEMENT ACTIVATION; DRUG DOSE TITRATION; DRUG MECHANISM; HEART SURGERY; HUMAN; HYPOTENSION; LUNG VASOCONSTRICTION; PLATELET COUNT; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; TITRIMETRY; VASOPLEGIA; VISCOELASTICITY; CARDIOPULMONARY BYPASS; DOSE RESPONSE;

ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; POSTOPERATIVE HEMORRHAGE; PROTAMINES;

EID: 85045543054     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1016/j.bja.2018.01.023     Document Type: Review

References (125)

1. Balhorn, R., The protamine family of sperm nuclear proteins. Genome Biol, 8, 2007, 227.
2. Krayenbuhl, C., Rosenberg, T., Crystalline protamine insulin. Rep Steno Mem Hosp Nord Insulinlab 1 (1946), 60–73.
3. Thompson, W.H., Die physiologische Wirkung der Protamine und ihrer Spaltungsprodukte. Hoppe-Seyler's Ztschr fur Physiol Chem, 29, 1900, 1.
4. Waldschmidt-Leitz, E., Stadler, P., Steigerwaldt, F., Über Blutgerinnung, Hemmung und Beschleunigung. Z Physik Chem, 183, 1929, 39.
5. Chargaff, E., Olson, K.B., Studies on the chemistry of blood coagulation: VII. Studies on the action of heparin and other anticoagulants. The influence of protamine on the anticoagulant effect in vivo. J Biol Chem 122 (1937–1938), 153–167.
6. Parkin, T.W., Kvale, W.F., Neutralization of the anticoagulant effects of heparin with protamine (salmine). Am Heart J 37 (1949), 333–342.
7. Portmann, A.F., Holden, W.D., Protamine sulphate, heparin, and blood coagulation. J Clin Investig 28 (1949), 1451–1458.
8. Ferguson, J.H., The action of heparin, serum albumin (crystalline) and salmine on blood-clotting mechanism. Am J Physiol, 130, 1940, 759.
9. Tocantins, L.M., Cephalin, protamine and the antithromboplastic activity of normal and hemophilia plasmas. Proc Soc Exper Biol Med, 54, 1943, 94.
10. Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA), Boer, C., Meesters, M.I., et al. 2017 EACTS/EACTA guidelines on patient blood management for adult cardiac surgery. J Cardiothorac Vasc Anesth 32 (2018), 88–120.
11. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris, V.A., Brown, J.R., et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 91 (2011), 944–982.
12. Rossmann, P., Matousovic, K., Horácek, V., Protamine-heparin aggregates. Their fine structure, histochemistry, and renal deposition. Virchows Arch B Cell Pathol Incl Mol Pathol 40 (1982), 81–98.
13. Okajima, Y., Kanayama, S., Maeda, Y., et al. Studies on the neutralizing mechanism of antithrombin activity of heparin by protamine. Thromb Res 24 (1981), 21–29.
14. Kitani, T., Nagarajan, S.C., Shanberge, J.N., Effect of protamine on heparin-antithrombin III complexes. In vitro studies. Thromb Res 17 (1980), 367–374.
15. Kitani, T., Nagarajan, S.C., Shanberge, J.N., Effect of protamine on heparin antithrombin III complexes. In vivo studies. Thromb Res 17 (1980), 375–382.
16. Zaidan, J.R., Johnson, S., Brynes, R., Monroe, S., Guffin, A.V., Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery. Anesth Analg 65 (1986), 377–380.
17. Shanberge, J.N., Quattrociocchi-Longe, T.M., Influence of platelet factor 4 on the neutralization of heparin by protamine. Ann N Y Acad Sci 556 (1989), 354–365.
18. Butterworth, J., Lin, Y.A., Prielipp, R., Bennett, J., James, R., The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. Anesth Analg 94 (2002), 514–522.
19. Butterworth, J., Lin, Y.A., Prielipp, R.C., Bennett, J., Hammon, J.W., James, R.L., Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. Ann Thorac Surg 74 (2002), 1589–1595.
20. Schroeder, M., Hogwood, J., Gray, E., Mulloy, B., Hackett, A.M., Johansen, K.B., Protamine neutralisation of low molecular weight heparins and their oligosaccharide components. Anal Bioanal Chem 399 (2011), 763–771.
21. Stehle, G., Wunder, A., Sinn, H., et al. Complexes of a modified low-molecular-weight heparin with protamine are predominantly cleared by a macrophage scavenger receptor-mediated process in rats. J Surg Res 58 (1995), 197–204.
22. DeLucia, A. 3rd, Wakefield, T.W., Kadell, A.M., Wrobleski, S.K., VanDort, M., Stanley, J.C., Tissue distribution, circulating half-life, and excretion of intravenously administered protamine sulfate. ASAIO J 39 (1993), 715–718.
23. Jacques, L.B., A study of the toxicity of the protamine salmine. Br J Pharmacol 4 (1949), 135–144.
24. Lindblad, B., Wakefield, T.W., Whitehouse, W.M. Jr., Stanley, J.C., The effect of protamine sulfate on platelet function. Scand J Thorac Cardiovasc Surg 22 (1988), 55–59.
25. Ammar, T., Fisher, C.F., The effects of heparinase 1 and protamine on platelet reactivity. Anesthesiology 86 (1997), 1382–1386.
26. Shigeta, O., Kojima, H., Hiramatsu, Y., et al. Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg 118 (1999), 354–360.
27. Barstad, R.M., Stephens, R.W., Hamers, M.J., Sakariassen, K.S., Protamine sulfate inhibits platelet membrane glycoprotein Ib-von Willebrand factor activity. Thromb Haemost 83 (2000), 334–337.
28. Olsson, A., Alfredsson, J., Håkansson, E., Svedjeholm, R., Berglund, J., Berg, S., Protamine reduces whole blood platelet aggregation after cardiopulmonary bypass. Scand Cardiovasc J 50 (2016), 58–63.
29. ®) in patients undergoing cardiopulmonary bypass. Anesth Analg 116 (2013), 533–540.
30. Mochizuki, T., Olson, P.J., Szlam, F., Ramsay, J.G., Levy, J.H., Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 87 (1998), 781–785.
31. Storck, J., Höllger, N., Zimmermann, R.E., The influence of heparin and protamine sulfate on platelet ADP and platelet factor 4 release and the expression of glycoprotein IIb/IIIa. Haemostasis 24 (1994), 358–363.
32. Cobel-Geard, R.J., Hassouna, H.I., Interaction of protamine sulfate with thrombin. Am J Hematol 14 (1983), 227–233.
33. Matsuo, T., Shanberge, J.N., Matsuo, O., Effect of protamine sulfate on antithrombin III activity. Clin Chim Acta 131 (1983), 233–238.
34. Ni Ainle, F., Preston, R.J., Jenkins, P.V., et al. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood 114 (2009), 1658–1665.
35. Chu, A.J., Wang, Z.G., Raicu, M., Beydoun, S., Ramos, N., Protamine inhibits tissue factor-initiated extrinsic coagulation. Br J Haematol 115 (2001), 392–399.
36. Misgav, M., Mandelbaum, T., Kassif, Y., Berkenstadt, H., Tamarin, I., Kenet, G., Thromboelastography during coronary artery bypass grafting surgery of severe hemophilia A patient—the effect of heparin and protamine on factor VIII activity. Blood Coagul Fibrinolysis 28 (2017), 329–333.
37. Meesters, M.I., Veerhoek, D., de Lange, F., et al. Effect of high or low protamine dosing on postoperative bleeding following heparin anticoagulation in cardiac surgery. A randomised clinical trial. Thromb Haemost 116 (2016), 251–261.
38. Bolliger, D., Szlam, F., Azran, M., et al. The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations. Anesth Analg 111 (2010), 601–608.
39. Nielsen, V.G., Malayaman, S.N., Protamine sulfate: crouching clot or hidden hemorrhage?. Anesth Analg 111 (2010), 593–594.
40. Mittermayr, M., Margreiter, J., Velik-Salchner, C., et al. Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem): an in vitro study. Br J Anaesth 95 (2005), 310–316.
41. Meesters, M.I., Lancé M.D., van der Steeg, R., Boer, C., The value of the thromboelastometry heparinase assay (HEPTEM) in cardiac surgery. Thromb Haemost 114 (2015), 1058–1063.
42. Mittermayr, M., Velik-Salchner, C., Stalzer, B., et al. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study. Anesth Analg 108 (2009), 743–750.
43. Khan, N.U., Wayne, C.K., Barker, J., Strang, T., The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph. Eur J Anaesthesiol 27 (2010), 624–627.
44. Nielsen, V.G., Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation. Ann Thorac Surg 81 (2006), 1720–1727.
45. Nielsen, V.G., Malayaman, S.N., Cohen, J.B., Persaud, J.M., Carbon monoxide releasing molecule-2 improves protamine-mediated hypocoagulation/hyperfibrinolysis in human plasma in vitro. J Surg Res 173 (2012), 232–239.
46. Nybo, M., Madsen, J.S., Serious anaphylactic reactions due to protamine sulfate: a systematic literature review. Basic Clin Pharmacol Toxicol 103 (2008), 192–196.
47. Brück, S., Skrabal, C., Träger, K., Reinelt, H., Risk factors for adverse reactions after protamine administration in adult patients undergoing cardiac surgery—a case report and literature review. Anasthesiol Intensivmed Notfallmed Schmerzther 49 (2014), 360–366.
48. Nyhan, D.P., Shampaine, E.L., Hirshman, C.A., et al. Single doses of intravenous protamine result in the formation of protamine-specific IgE and IgG antibodies. J Allergy Clin Immunol 97 (1996), 991–997.
49. Lee, G.M., Welsby, I.J., Phillips-Bute, B., Ortel, T.L., Arepally, G.M., High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass. Blood 121 (2013), 2828–2835.
50. Lee, G.M., Joglekar, M., Khandelwal, S., Qi, R., Rauova, L., Arepally, G.M., Characterization of human and murine anti-protamine/heparin antibodies. Blood, 126, 2015, 3461.
51. Bakchoul, T., Zöllner, H., Amiral, J., et al. Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis. Blood 121 (2013), 2821–2827.
52. Pouplard, C., Leroux, D., Rollin, J., Amiral, J., May, M.A., Gruel, Y., Incidence of antibodies to protamine sulfate/heparin complexes in cardiac surgery patients and impact on platelet activation and clinical outcome. Thromb Haemost 109 (2013), 1141–1147.
53. Grieshaber, P., Bakchoul, T., Wilhelm, J., et al. Platelet-activating protamine-heparin-antibodies lead to higher protamine demand in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 150 (2015), 967–973.
54. Panzer, S., Schiferer, A., Steinlechner, B., Drouet, L., Amiral, J., Serological features of antibodies to protamine inducing thrombocytopenia and thrombosis. Clin Chem Lab Med 53 (2015), 249–255.
55. Al-Mondhiry, H., Pierce, W.S., Basarab, R.M., Protamine-induced thrombocytopenia and leukopenia. Thromb Haemost 53 (1985), 60–64.
56. Singla, A., Sullivan, M.J., Lee, G., et al. Protamine-induced immune thrombocytopenia. Transfusion 53 (2013), 2158–2163.
57. Koster, A., Rosendahl, U., von Hodenberg, E., Ennker, J., Management of protamine allergy with bivalirudin during coronary artery revascularization. Ann Thorac Surg 90 (2010), 276–277.
58. Bruins, P., te Velthuis, H., Yazdanbakhsh, A.P., et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 96 (1997), 3542–3548.
59. Bruins, P., te Velthuis, H., Eerenberg-Belmer, A.J., et al. Heparin-protamine complexes and C-reactive protein induce activation of the classical complement pathway: studies in patients undergoing cardiac surgery and in vitro. Thromb Haemost 84 (2000), 237–243.
60. Best, N., Sinosich, M.J., Teisner, B., Grudzinskas, J.G., Fisher, M.M., Complement activation during cardiopulmonary bypass by heparin-protamine interaction. Br J Anaesth 56 (1984), 339–343.
61. Cavarocchi, N.C., Schaff, H.V., Orszulak, T.A., Homburger, H.A., Schnell, W.A. Jr., Pluth, J.R., Evidence for complement activation by protamine-heparin interaction after cardiopulmonary bypass. Surgery 98 (1985), 525–531.
62. Ovrum, E., Lindberg, H., Holen, E.A., Abdelnoor, M., Bech, J., Systemic and pulmonary circulatory effects of protamine following cardiopulmonary bypass in man. Scand J Thorac Cardiovasc Surg 25 (1991), 19–24.
63. Murase, K., Naruse, K., Kimura, A., Okumura, K., Hayakawa, T., Sokabe, M., Protamine augments stretch induced calcium increase in vascular endothelium. Br J Pharmacol 134 (2001), 1403–1410.
64. Pevni, D., Gurevich, J., Frolkis, I., et al. Protamine induces vasorelaxation of human internal thoracic artery by endothelial NO-synthase pathway. Ann Thorac Surg 70 (2000), 2050–2053.
65. Stawicki, S.P., Sims, C., Sarani, B., Grossman, M.D., Gracias, V.H., Methylene blue and vasoplegia: who, when, and how?. Mini Rev Med Chem 8 (2008), 472–490.
66. Comunale, M.E., Maslow, A., Robertson, L.K., Haering, J.M., Mashikian, J.S., Lowenstein, E., Effect of site of venous protamine administration, previously alleged risk factors, and preoperative use of aspirin on acute protamine-induced pulmonary vasoconstriction. J Cardiothorac Vasc Anesth 17 (2003), 309–313.
67. Ocal, A., Kiriş I., Erdinç M., Peker, O., Yavuz, T., Ibrişim, E., Efficiency of prostacyclin in the treatment of protamine-mediated right ventricular failure and acute pulmonary hypertension. Tohoku J Exp Med 207 (2005), 51–58.
68. Morel, D.R., Lowenstein, E., Nguyenduy, T., et al. Acute pulmonary vasoconstriction and thromboxane release during protamine reversal of heparin anticoagulation in awake sheep. Circ Res 62 (1988), 905–915.
69. Montalescot, G., Lowenstein, E., Ogletree, M.L., et al. Thromboxane receptor blockade prevents pulmonary hypertension induced by heparin-protamine reactions in awake sheep. Circulation 82 (1990), 1765–1777.
70. Nuttall, G.A., Murray, M.J., Bowie, E.J., Protamine-heparin-induced pulmonary hypertension in pigs: effects of treatment with a thromboxane receptor antagonist on hemodynamics and coagulation. Anesthesiology 74 (1991), 138–145.
71. Lowenstein, E., Zapol, W.M., Protamine reactions, explosive mediator release, and pulmonary vasoconstriction. Anesthesiology 73 (1990), 373–375.
72. Abe, K., Sakakibara, T., Miyamoto, Y., Ohnishi, K., Effect of prostaglandin E1 on pulmonary hypertension after protamine injection during cardiac surgery. Eur J Clin Pharmacol 54 (1998), 21–25.
73. Wakefield, T.W., Hantler, C.B., Wrobleski, S.K., Crider, B.A., Stanley, J.C., Effects of differing rates of protamine reversal of heparin anticoagulation. Surgery 119 (1996), 123–128.
74. Chaney, M.A., Devin Roberts, J., Wroblewski, K., Shahul, S., Gaudet, R., Jeevanandam, V., Protamine administration via the ascending aorta may prevent cardiopulmonary instability. J Cardiothorac Vasc Anesth 30 (2016), 647–655.
75. Yamamoto, T., Wolf, H.G., Sinzobahamvya, N., Asfour, B., Hraska, V., Schindler, E., Prolonged activated clotting time after protamine administration does not indicate residual heparinization after cardiopulmonary bypass in pediatric open heart surgery. Thorac Cardiovasc Surg 63 (2015), 397–403.
76. Murray, D.J., Brosnahan, W.J., Pennell, B., et al. Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays. J Cardiothorac Vasc Anesth 11 (1997), 24–28.
77. Despotis, G.J., Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 108 (1994), 1076–1082.
78. Fitzgerald, D.J., Patel, A., Body, S.C., Garvin, S., The relationship between heparin level and activated clotting time in the adult cardiac surgery population. Perfusion 24 (2009), 93–96.
79. Vonk, A.B., Veerhoek, D., van den Brom, C.E., van Barneveld, L.J., Boer, C., Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery. J Cardiothorac Vasc Anesth 28 (2014), 235–241.
80. Keeler, J.F., Shah, M.V., Hansbro, S.D., Protamine—the need to determine the dose. Comparison of a simple protamine titration method with an empirical dose regimen for reversal of heparinisation following cardiopulmonary bypass. Anaesthesia 46 (1991), 925–928.
81. Miyashita, T., Nakajima, T., Hayashi, Y., Kuro, M., Hemostatic effects of low-dose protamine following cardiopulmonary bypass. Am J Hematol 64 (2000), 112–115.
82. Gertler, R., Wiesner, G., Tassani-Prell, P., Braun, S.L., Martin, K., Are the point-of-care diagnostics MULTIPLATE and ROTEM valid in the setting of high concentrations of heparin and its reversal with protamine?. J Cardiothorac Vasc Anesth 25 (2011), 981–986.
83. Levin, A.I., Heine, A.M., Coetzee, J.F., Coetzee, A., Heparinase thromboelastography compared with activated coagulation time for protamine titration after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 28 (2014), 224–229.
84. Despotis, G.J., Filos, K.S., Zoys, T.N., Hogue, C.W. Jr., Spitznagel, E., Lappas, D.G., Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 82 (1996), 13–21.
85. Svenarud, P., Øvrum, E., Clinical effects of different protamine doses after cardiopulmonary bypass. Asian Cardiovasc Thorac Ann 10 (2002), 119–123.
86. Von Segesser, L.K., Weiss, B.M., Pasic, M., Garcia, E., Turina, M.I., Risk and benefit of low systemic heparinization during open heart operations. Ann Thorac Surg 58 (1994), 391–397.
87. Aldea, G.S., Doursounian, M., O'Gara, P., et al. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study. Ann Thorac Surg 62 (1996), 410–417.
88. Aldea, G.S., O'Gara, P., Shapira, O.M., et al. Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits. Ann Thorac Surg 65 (1998), 425–433.
89. Delavenne, X., Ollier, E., Chollet, S., et al. Pharmacokinetic/pharmacodynamic model for unfractionated heparin dosing during cardiopulmonary bypass. Br J Anaesth 118 (2017), 705–712.
90. Jia, Z., Tian, G., Ren, Y., Sun, Z., Lu, W., Hou, X., Pharmacokinetic model of unfractionated heparin during and after cardiopulmonary bypass in cardiac surgery. J Transl Med, 13, 2015, 45.
91. Suárez Cuenca, J., Gayoso Diz, P., Gude Sampedro, F., Gómez Zincke, J.M., Rey Acuña, H., Fontanillo, M.M., Method to calculate the protamine dose necessary for reversal of heparin as a function of activated clotting time in patients undergoing cardiac surgery. J Extra Corpor Technol 45 (2013), 235–241.
92. Bull, B.S., Huse, W.M., Brauer, F.S., Heparin therapy during extracorporeal circulation: II. The use of a dose–response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 69 (1975), 685–689.
93. Kjellberg, G., Sartipy, U., van der Linden, J., Nissborg, E., Lindvall, G., An adjusted calculation model allows for reduced protamine doses without increasing blood loss in cardiac surgery. Thorac Cardiovasc Surg 64 (2016), 487–493.
94. Davidsson, F.Ö., Johagen, D., Appelblad, M., Svenmarker, S., Reversal of heparin after cardiac surgery: protamine titration using a statistical model. J Cardiothorac Vasc Anesth 29 (2015), 710–714.
95. Hällgren, O., Svenmarker, S., Appelblad, M., Implementing a statistical model for protamine titration: effects on coagulation in cardiac surgical patients. J Cardiothorac Vasc Anesth 1 (2017), 516–521.
96. Meesters, M.I., Veerhoek, D., de Jong, J.R., Boer, C., A pharmacokinetic model for protamine dosing after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 30 (2016), 1190–1195.
97. Maurer, J., Haselbach, S., Klein, O., Baykut, D., Vogel, V., Mäntele, W., Analysis of the complex formation of heparin with protamine by light scattering and analytical ultracentrifugation: implications for blood coagulation management. J Am Chem Soc 133 (2011), 1134–1140.
98. Guarracino, F., De Cosmo, D., Penzo, D., et al. Automated protamine dose assay in heparin reversal management after cardiopulmonary bypass. Minerva Anestesiol 67 (2001), 165–169.
99. Radulovic, V., Laffin, A., Hansson, K.M., Backlund, E., Baghaei, F., Jeppsson, A., Heparin and protamine titration does not improve haemostasis after cardiac surgery: a prospective randomized study. PLoS One, 10, 2015, e0130271.
100. Hoenicka, M., Rupp, P., Müller-Eising, K., et al. Anticoagulation management during multivessel coronary artery bypass grafting: a randomized trial comparing individualized heparin management and conventional hemostasis management. J Thromb Haemost 13 (2015), 1196–1206.
101. Koster, A., Börgermann, J., Gummert, J., Rudloff, M., Zittermann, A., Schirmer, U., Protamine overdose and its impact on coagulation, bleeding, and transfusions after cardiopulmonary bypass: results of a randomized double-blind controlled pilot study. Clin Appl Thromb Hemost 20 (2014), 290–295.
102. Hofmann, B., Bushnaq, H., Kraus, F.B., et al. Immediate effects of individualized heparin and protamine management on hemostatic activation and platelet function in adult patients undergoing cardiac surgery with tranexamic acid antifibrinolytic therapy. Perfusion 28 (2013), 412–418.
103. Noui, N., Zogheib, E., Walczak, K., et al. Anticoagulation monitoring during extracorporeal circulation with the Hepcon/HMS device. Perfusion 27 (2012), 214–220.
104. Runge, M., Møller, C.H., Steinbrüchel, D.A., Increased accuracy in heparin and protamine administration decreases bleeding: a pilot study. J Extra Corpor Technol 41 (2009), 10–14.
105. Slight, R.D., Buell, R., Nzewi, O.C., McClelland, D.B., Mankad, P.S., A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth 22 (2008), 47–52.
106. Pappalardo, F., Franco, A., Crescenzi, G., De Simone, F., Torracca, L., Zangrillo, A., Anticoagulation management in patients undergoing open heart surgery by activated clotting time and whole blood heparin concentration. Perfusion 21 (2006), 285–290.
107. Avidan, M.S., Alcock, E.L., Da Fonseca, J., et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth 92 (2004), 178–186.
108. Koster, A., Fischer, T., Praus, M., et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology 97 (2002), 837–841.
109. Beholz, S., Grubitzsch, H., Bergmann, B., Wollert, H.G., Eckel, L., Hemostasis management by use of Hepcon/HMS: increased bleeding without increased need for blood transfusion. Thorac Cardiovasc Surg 47 (1999), 322–327.
110. Shore-Lesserson, L., Reich, D.L., DePerio, M., Heparin and protamine titration do not improve haemostasis in cardiac surgical patients. Can J Anaesth 45 (1998), 10–18.
111. Despotis, G.J., Joist, J.H., Hogue, C.W. Jr., et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 110 (1995), 46–54.
112. DeLaria, G.A., Tyner, J.J., Hayes, C.L., Armstrong, B.W., Heparin-protamine mismatch. A controllable factor in bleeding after open heart surgery. Arch Surg 129 (1994), 944–950.
113. Higgins, J.P., Altman, D.G., Gotzsche, P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Br Med J, 343, 2011, d5928.
114. Berger, R.L., Ramaswamy, K., Ryan, T.J., Reduced protamine dosage for heparin neutralization in open-heart operations. Circulation 37 (1968), 154–157.
115. Jobes, D.R., Aitken, G.L., Shaffer, G.W., Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 110 (1995), 36–45.
116. Taneja, R., Marwaha, G., Sinha, P., et al. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery. Can J Anaesth 56 (2009), 489–496.
117. Ichikawa, J., Kodaka, M., Nishiyama, K., et al. Reappearance of circulating heparin in whole blood heparin concentration-based management does not correlate with postoperative bleeding after cardiac surgery. J Cardiothorac Vasc Anesth 28 (2014), 1003–1007.
118. Teoh, K.H., Young, E., Blackall, M.H., Roberts, R.S., Hirsh, J., Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?. J Thorac Cardiovasc Surg 128 (2004), 211–219.
119. Warkentin, T.E., Greinacher, A., Koster, A., Bivalirudin Thromb Haemost 99 (2008), 830–839.
120. Dyke, C.M., Smedira, N.G., Koster, A., et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. Thorac Cardiovasc Surg 131 (2006), 533–539.
121. Koster, A., Dyke, C.M., Aldea, G., et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 83 (2007), 572–577.
122. Sokolowska, E., Kalaska, B., Miklosz, J., Mogielnicki, A., The toxicology of heparin reversal with protamine: past, present and future. Expert Opin Drug Metab Toxicol 12 (2016), 897–909.
123. Levy, J.H., Cormack, J.G., Morales, A., Heparin neutralization by recombinant platelet factor 4 and protamine. Anesth Analg 81 (1995), 35–37.
124. Stafford-Smith, M., Lefrak, E.A., Qazi, A.G., et al. Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass. Anesthesiology 103 (2005), 229–240.
125. Kikura, M., Lee, M.K., Levy, J.H., Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass. Anesth Analg 83 (1996), 223–227.